The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K. Baumgartner, Joshua H. Decker, Hakimeh Ebrahimi-Nik et al.|Nature|2023Cited by 170
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunityMeng‐Ju Wu, Nabeel Bardeesy, Hyo Min Cho et al.|Science|2024Cited by 87
DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional ReprogrammingIlaria Gritti, Nabeel Bardeesy, Jinkai Wan et al.|Cancer Discovery|2024Cited by 14
Data from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional ReprogrammingIlaria Gritti, Nabeel Bardeesy, Jinkai Wan et al.|Unknown|2025Cited by 3
Correction: DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional ReprogrammingIlaria Gritti, Nabeel Bardeesy, Jinkai Wan et al.|Cancer Discovery|2025Cited by 0